EXP01-AD: Weekly SC MSC-EV Lead with Topical Option for Atopic Dermatitis

EXORPHIA develops extracellular-vesicle (EV) therapeutics supported by integrated EV manufacturing and CMC/QC capabilities.

EXP01-AD is a nonclinical MSC-derived EV ("Prime-EV") candidate for atopic dermatitis. The 2026 update adds a low-dose, once-weekly subcutaneous proof of concept. We now prioritize the subcutaneous route as the lead program for systemic disease control, with once-daily topical administration retained as a complementary local-treatment option.

Nonclinical evidence

• In a severe AD mouse study with an oral abrocitinib comparator group, once-weekly subcutaneous dosing at 1/100 of the previously tested nonclinical dose reduced TEWL by 77.7% versus vehicle at Day 30, brought TEWL close to the normal-group range, and significantly suppressed inflammatory skin thickening.

• In the topical study, once-daily dosing at 1/100 of the previously tested nonclinical dose, using test article stored at 25°C for two months, brought TEWL close to the normal-group range and significantly improved total clinical score AUC versus vehicle. Point-by-point score differences were not statistically significant.

• Exploratory tolerability assessments showed no clear body-weight loss or thymus-weight reduction under the evaluated conditions.

Why partner now

The low-dose systemic PoC creates an opportunity to shape the translational strategy before the program is locked. An early pharmaceutical partner can help define the systemic target product profile, MoA/target-engagement package, skin-distribution and human-translatability work, development candidate criteria, and IND-enabling plan. EXORPHIA contributes its EV platform, patent applications, QC marker candidates under evaluation for association with potency, and ongoing CMC/QC development.

Partnering opportunity

We are seeking global or regional licensing and co-development discussions at the nonclinical stage. The subcutaneous program is the lead; topical development can be included as an option.

Nonclinical results only. Clinical efficacy and safety have not been established.